Basaglar is manufactured by Eli Lilly and Company [1].
What is Basaglar?
Basaglar is a brand name for insulin glargine, a long-acting insulin used to manage blood sugar levels in adults and children with diabetes [2]. It is a biosimilar to Lantus (insulin glargine) [3].
When did Basaglar's patents expire?
The patent landscape for Basaglar, specifically insulin glargine, is complex and has involved multiple patents and legal challenges. For instance, patents related to the manufacturing of insulin glargine and its formulations have been litigated. Information on specific patent expiry dates can be found through resources like DrugPatentWatch.com [4].
How does Basaglar compare to Lantus?
Basaglar is a biosimilar to Lantus. Biosimilars are highly similar to an already approved reference product, with no clinically meaningful differences in safety, purity, and potency [3]. This means Basaglar is expected to have the same clinical effect as Lantus [3].
Are there other biosimilars for insulin glargine?
Yes, other biosimilars for insulin glargine have been approved. These include Semglee, also manufactured by Eli Lilly and Company, and Admelog, produced by Sanofi [3][5]. The availability of multiple biosimilars can increase competition and potentially lower costs for patients [6].
What is the mechanism of action for insulin glargine?
Insulin glargine is an analog of human insulin designed to provide a prolonged, relatively constant plasma concentration of insulin over 24 hours [7]. It works by mimicking the action of endogenous insulin, facilitating glucose uptake into cells, and reducing hepatic glucose production [7]. This helps to lower blood glucose levels [7].
What are the potential side effects of Basaglar?
The most common side effect associated with Basaglar, like other insulins, is hypoglycemia (low blood sugar) [2]. Other potential side effects include injection site reactions, lipodystrophy, and allergic reactions [2].
Where can I find more information on drug patents and exclusivity?
DrugPatentWatch.com offers comprehensive data on drug patents, exclusivity periods, and patent litigation for a wide range of pharmaceutical products, including insulins and their biosimilars [4].
Sources:
[1] https://www.drugpatentwatch.com/drug/basaglar
[2] https://www.drugs.com/basaglar.html
[3] https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-insulin-product
[4] https://www.drugpatentwatch.com/
[5] https://www.drugs.com/newdrugs/eli-lilly-sanofi-launch-admelog-insulin-glargine-injection-4590
[6] https://www.fda.gov/news-events/public-health-focus/biosimilars
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2784276/